MRK

Merck KGaA is the oldest pharmaceutical and chemical company in the world, founded in 1668 in Darmstadt, Germany, and still controlled by the Merck family through E. Merck KG. It is also one of the most structurally misunderstood companies in European equity markets. The confusion begins with the name: in the United States, Merck KGaA operates as EMD Serono (Healthcare), MilliporeSigma (Life Science), and EMD Electronics, a naming complexity that arose from the historical split with Merck & Co. during World War I. But the deeper misunderstanding is strategic. Investors and analysts frequently attempt to value Merck KGaA as a pharmaceutical company, comparing it with Roche, Novartis, or Sanofi. This framing misses the structural reality. Merck KGaA is not primarily a drugmaker. It is an infrastructure provider to three distinct industries: biopharmaceutical manufacturing, academic research, and semiconductor fabrication.

This is a company that does not need to win the drug development race; it supplies the reagents, filters, chromatography resins, and process development expertise to every company that does. It does not need to design the most advanced chip; it provides the specialty chemicals and materials that make advanced lithography possible. The central analytical question for Merck KGaA is not whether its next oncology drug will succeed, but whether the structural demand for its consumables and materials can compound faster than the cyclical headwinds in its end markets. With fiscal year 2025 revenue of EUR 21.1 billion, EBITDA of EUR 5.95 billion, and a market capitalization near EUR 49 billion, the company sits at a valuation crossroads where the market prices it like a mature pharmaceutical conglomerate while the underlying business increasingly resembles a toll-road operator across high-growth scientific and technological workflows.

The L17X insight is this: Merck KGaA's three segments appear unrelated on a product level, but they share a single structural advantage. In each case, the company has inserted itself into regulated, quality-critical workflows where switching costs are not defined by price, but by revalidation risk. A biopharmaceutical manufacturer does not change its filter supplier mid-production. A semiconductor fab does not swap its photoresist vendor between node transitions. The cost of Merck KGaA's products is trivial relative to the cost of failure in the processes they enable. This asymmetry is the company's true moat.